Zimmer Biomet ($ZBH) has acquired CD Diagnostics for an undisclosed sum. The musculoskeletal healthcare company has taken on the diagnostics company focused on immunoassays and biomarker testing with the aim of boosting musculoskeletal diagnostics.
The two have partnered in the past, working to develop and market diagnostics in musculoskeletal healthcare in 2012. During that time, Zimmer marketed the Synovasure Periprosthetic Joint Infection (PJI) test, designed to diagnose PJI. Zimmer Biomet designs, manufactures and markets multiple musculoskeletal products including orthopedic reconstructive products, dental implants and more.
"I formed CD Diagnostics to solve the frustrating problem of diagnosing PJI and the complications associated with misdiagnosis, including the pain and incremental costs-of-care following joint replacement surgery,” Carl Deirmengian, scientific founder of CD Diagnostics, said in a statement.
He continued, “As a leader and visionary in musculoskeletal healthcare, Zimmer Biomet is the ideal partner to leverage our expertise in biomarker detection and immunoassay development, and to elevate the value of diagnostics in the treatment of musculoskeletal conditions.”
CD works to analyze biomarker profiles of synovial fluid. Synovial fluid reduces friction between articular cartilage. CD creates diagnostic assays to aid physicians in decision-making and patient care.
Thorsten Gehrke of the Helios Indo-Klinik in Hamburg, Germany, noted that the Synovasure test helps to “detect the periprosthetic infection with high accuracy.” He also noted that with this test, he is able to tell a patient if they have an infection within hours of testing.
"We're excited to team up with CD Diagnostics to accelerate the pace of innovation in musculoskeletal diagnostics, ramp up adoption of testing into standard protocols, and arm surgeons with critical data to inform diagnosis, staging, treatment and recovery,” Dan Williamson, group president of joint reconstruction for Zimmer Biomet said in the announcement. Williamson also noted that the acquisition will help to strengthen Zimmer Biomet’s Signature Solutions offering.
- here's the release